The COVID-19 Registry Japan (COVIREGI-JP), a registry of patients hospitalized with coronavirus disease (COVID-19), contains the largest national COVID-19 inpatient population. Since COVIREGI- JP invites voluntary participation by facilities, selection bias is inevitable. The current study examined the representativeness of COVIREGI-JP data in comparison to open-source national data. The number of infections and deaths among hospitalized COVID-19 patients in COVIREGI-JP were compared to those in national data recorded during the six waves of the COVID-19 epidemic until March 6, 2022. During the period studied, patients in COVIREGI-JP represented 1% of the total COVID-19 cases according to national data; the proportion was high during the first wave (32.7%) and tended to decrease, especially after the fourth wave. The overall proportion of patients from each region varied from 0.8% to 2.5%, but case fatality rates in COVIREGI-JP tended to be higher than those in the national data, with the exception of a few waves, in several regions. The difference was smallest during the first wave. Although COVIREGI-JP consistently registered cases from all regions of the country, the proportion tended to decline after the beginning of the epidemic. Given the epidemiological persistence and the ever-changing epidemiology of COVID-19, continued case registration and data utilization in COVIREGI-JP is desirable, although selection bias in COVIREGI-JP registration of cases should be carefully interpreted.
He was diagnosed with adhesive bowel obstruction, which was treated conservatively and the patient recovered
M/22
Tonsillitis
29
Serious
Related/cannot be ruled out
The subject with no previous medical history presented with mild sore throat and fever appearing on Day 6 post-vaccination, which was judged to have been caused by the vaccination by the site physician. No adverse event occurred to the baby
ht Onset time is counted from vaccination day (vaccination = Day 0). He was diagnosed with adhesive bowel obstruction, which was treated conservatively and the patient recovered
M/22
Tonsillitis
29
Serious
Related/cannot be ruled out
The subject with no previous medical history presented with mild sore throat and fever appearing on Day 6 post-vaccination, which was judged to have been caused by the vaccination by the site physician. On 24 July 2017, Sanofi Pasteur, yellow fever vaccine (YF-VAX) manufacturer, announced a vaccine shortage caused by manufacturing delays.[1] Consequently, some countries were forced to take compensatory measures. [Extracted from the article]